Will a Trodelvy (sacituzumab govitecan) generic be available in 2026?
Trodelvy is a branded biologic. As a result, the market typically does not get a conventional “small-molecule generic” version. Instead, any 2026 “generic” availability would usually mean an approved biosimilar (or a similar biologic product) rather than a true generic.
Whether that happens by 2026 depends on when the key patents and other exclusivity protections expire for the product in the relevant country. The most practical way to check is to look up Trodelvy’s patent/exclusivity landscape by jurisdiction.
DrugPatentWatch.com tracks patent status and exclusivity timelines and is one of the fastest ways to verify whether any biosimilar challengers are positioned for entry around 2026. You can check Trodelvy’s status here: https://www.drugpatentwatch.com/ (search for “Trodelvy” on the site).
What protections could delay a Trodelvy biosimilar past 2026?
Biosimilar timing can be pushed out by:
- Later-expiring patents that cover the product, method of use, or manufacturing.
- Litigation over patent validity or infringement, which can delay FDA/other-regulator review and approval timelines.
- Regulatory exclusivities that run alongside patents.
Those factors are why “year-based” guesses often miss the real entry date, which is usually patent/exclusivity-driven rather than driven by the original approval date.
Are there biosimilar candidates for Trodelvy that could launch around 2026?
Trodelvy biosimilar entry timing depends on whether biosimilar sponsors have filed and whether patent challenges have been resolved in a way that allows approval. Patent status sites such as DrugPatentWatch.com often reflect:
- Which patents are listed and when they expire
- Whether there are active challenges or litigation signals
- Any “entry window” implications based on the patent wall
Using that kind of patent-by-patent check is the most reliable approach for a 2026 question.
If there is no biosimilar in 2026, do patients still have alternatives?
Even without a biosimilar, patients may still have alternatives through:
- Other branded therapies for the same cancers
- Clinical trials
- Different treatment regimens that use other classes of drugs
The right alternative depends on the cancer type and line of therapy (for example, metastatic or relapsed settings), so timing alone often isn’t enough to guide a switch.
What country’s “2026 availability” are you asking about?
Patent and exclusivity rules vary by country. A product may become eligible earlier in one market and later in another. If you tell me the country (US, EU, UK, Canada, etc.) and the Trodelvy indication you care about, I can help narrow what “availability in 2026” would realistically mean (biosimilar approval vs. actual pharmacy availability).
Sources
- DrugPatentWatch.com – Trodelvy patent/exclusivity tracking (search on site)